Does minor histocompatibility antigen HA‐1 disparity affect the occurrence of graft‐versus‐host disease in tunisian recipients of hematopoietic stem cells?

INTRODUCTION: Minor histocompatibility antigen HA‐1 (MiHAg‐HA‐1) disparity between a patient and his or her human leukocyte antigen (HLA) genoidentical donor has been widely associated with an increased risk of graft‐versus‐host disease following allogeneic hematopoietic stem cell transplantation. OBJECTIVE: To examine the effect of HA‐1 disparity on the incidence of both acute and chronic graft‐versus‐host disease in Tunisian recipients of hematopoietic stem cells. METHODS: A total of 60 patients and their 60 respective sibling hematopoietic stem cell donors were enrolled in this study. All patients prophylactically received cyclosporine A and/or methotrexate for graft‐versus‐host disease. An HA‐1 genotyping assay was performed with the SSP‐PCR method, and HLA‐A*0201‐ and/or HLA‐A*0206‐positive samples were identified using the Luminex HLA typing method. RESULTS: The Luminex HLA typing assay showed that 54 patients were positive for either the HLA‐A*0201 or HLA‐A*0206 alleles. Among these cases, six pairs were mismatched for MiHAg‐HA‐1. Both acute and chronic graft‐versus‐host disease occurred in four mismatched patients (Fisher's p‐values were 0.044 and 0.170, respectively). A univariate logistic regression model analysis showed that only acute graft‐versus‐host disease may be affected by recipient MiHAg‐HA‐1 disparity (p: 0.041, OR: 6.727), while chronic graft‐versus‐host disease correlates with both age and recipient/donor sex mismatch (p: 0.014, OR: 8.556 and p: 0.033, OR: 8.664, respectively). CONCLUSION: Our findings support previously reported data suggesting a significant association between HA‐1 disparity and the risk of acute graft‐versus‐host disease following hematopoietic stem cell transplantation.

[1]  S. Hmida,et al.  HA-1 and HA-2 minor histocompatibility antigens in Tunisians. , 2010, Tissue antigens.

[2]  E. Warren,et al.  Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  P. Reddy,et al.  GVHD pathophysiology: is acute different from chronic? , 2008, Best practice & research. Clinical haematology.

[4]  P. Reddy,et al.  Pathophysiology of acute graft-versus-host disease: recent advances. , 2007, Translational research : the journal of laboratory and clinical medicine.

[5]  K. Monastiri,et al.  Interplay of socio-economic factors, consanguinity, fertility, and offspring mortality in Monastir, Tunisia. , 2007, Croatian medical journal.

[6]  Y. Kodera,et al.  The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A*0206 , 2007, Bone Marrow Transplantation.

[7]  L. Hambach,et al.  Risk assessment in haematopoietic stem cell transplantation: minor histocompatibility antigens. , 2007, Best practice & research. Clinical haematology.

[8]  W. Shlomchik,et al.  Graft-versus-host disease , 2007, Nature Reviews Immunology.

[9]  G. Reid,et al.  Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  J. Bay,et al.  Place des anticorps monoclonaux dans le traitement de la maladie aiguë du greffon contre l’hôte en 2006 , 2007 .

[11]  J. Bay,et al.  [Role of monoclonal antibodies in the treatment of acute graft versus host disease]. , 2007, Bulletin du cancer.

[12]  Y. Mosaad,et al.  Impact of CD31 mismatches on the outcome of hematopoeitic stem cell transplant of HLA-identical sibling , 2006, Hematology.

[13]  A. Hajjej,et al.  The contribution of HLA class I and II alleles and haplotypes to the investigation of the evolutionary history of Tunisians. , 2006, Tissue antigens.

[14]  Stephanie J. Lee.  New approaches for preventing and treating chronic graft-versus-host disease. , 2005, Blood.

[15]  C. Chapman,et al.  Donor CD31 genotype impacts on transplant complications after human leukocyte antigen-matched sibling allogeneic bone marrow transplantation. , 2005, Transplantation.

[16]  S. Malarkannan,et al.  Minor Histocompatibility Antigens: Molecular targets for immunomodulation in tissue transplantation and tumor therapy , 2005 .

[17]  Catherine J. Wu,et al.  Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. , 2004, Blood.

[18]  J. Ferrara,et al.  Pathophysiology of Acute Graft-vs-Host Disease , 2004 .

[19]  J. Falkenburg,et al.  Minor histocompatibility antigens in human stem cell transplantation. , 2003, Experimental hematology.

[20]  M. Andreani,et al.  Recipient mHag-HA1 disparity and aGVHD in thalassemic-transplanted patients , 2003, Bone Marrow Transplantation.

[21]  A. Gratwohl.  Prognostic factors in chronic myeloid leukemia: allografting. , 2003, Seminars in hematology.

[22]  J. Hansen,et al.  Absence of statistically significant correlation between disparity for the minor histocompatibility antigen-HA-1 and outcome after allogeneic hematopoietic cell transplantation. , 2001, Blood.

[23]  D. Scott,et al.  Minor H antigens: genes and peptides. , 2001, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[24]  A. Grañena,et al.  Disparity for the minor histocompatibility antigen HA‐1 is associated with an increased risk of acute graft‐versus‐host disease (GvHD) but it does not affect chronic GvHD incidence, disease‐free survival or overall survival after allogeneic human leucocyte antigen‐identical sibling donor transplanta , 2001, British journal of haematology.

[25]  A. Janin,et al.  Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. , 2001, Transplantation.

[26]  J. McCluskey,et al.  Clinical relevance of the minor histocompatibility antigen HA-1 in allogeneic bone marrow transplantation between HLA identical siblings. , 2001, Transplantation proceedings.

[27]  Anajane G. Smith,et al.  Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation. , 1999, Blood.

[28]  M. Wilke,et al.  Genomic identification of the minor histocompatibility antigen HA-1 locus by allele-specific PCR. , 1998, Tissue Antigens.

[29]  J. Hansen,et al.  Definition of the gene encoding the minor histocompatibility antigen HA-1 and typing for HA-1 from genomic DNA. , 1998, Tissue antigens.

[30]  Pj Martin.  How much benefit can be expected from matching for minor antigens in allogeneic marrow transplantation? , 1997, Bone Marrow Transplantation.

[31]  H. V. van Houwelingen,et al.  Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. , 1996, The New England journal of medicine.

[32]  J. Zehnder,et al.  Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease. , 1996, The New England journal of medicine.

[33]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[34]  M. Eisner,et al.  Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. , 1995, Bone marrow transplantation.

[35]  E. Goulmy.  Minor Histocompatibility antigens in man and their role in transplantation. , 1988 .